<DOC>
	<DOCNO>NCT00544544</DOCNO>
	<brief_summary>Bipolar disorder common often chronic debilitate mental illness . The depressive phase bipolar disorder contributes large portion disorder , treatment resistant bipolar depression represent significant public health problem . Recent research suggest bipolar depression associate elevate brain glutamate activity . We hypothesize riluzole , drug approve ALS inhibits glutamate activity , lead clinical improvement patient bipolar depression .</brief_summary>
	<brief_title>Riluzole Treatment Bipolar Depression</brief_title>
	<detailed_description>We hypothesize riluzole lead significant reduction depressive symptom measure Hamilton Depression Rating Scale ( HAM-D ) . Additionally , improvement depressive symptom associate reduced glutamate level anterior cingulate cortex , parieto-occipital cortex , day two day 42 .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Riluzole</mesh_term>
	<criteria>Male female age 1865 Meets DSMIV criterion Bipolar Disorder currently depress Current score &gt; /= 18 Hamilton Depression Scale Active psychotic/manic symptom Lifetime history schizophrenia obsessive compulsive disorder Clinically significant medical disease Women pregnant lactate woman use medically accept method contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Bipolar</keyword>
	<keyword>depression</keyword>
</DOC>